Yuyao YiJia, a Chinese OTC drug and hand sanitizer maker, lacked finished-product, component and stability testing and an adequate quality unit.
What happened
FDA found these problems by reviewing records the company submitted after FDA's March 31, 2020 request for records under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. FDA found the company did not adequately test finished drugs for identity and strength of active ingredients, did not test incoming components for identity, lacked stability data covering the active ingredient, and lacked adequate quality unit procedures. The company had shipped several lots of hand sanitizer to the United States.
What FDA found
The company released drug batches, including hand sanitizer shipped to the U.S., without adequate lab testing to confirm the identity and strength of the active ingredient.
21 CFR 211.165(a)The company did not test incoming raw materials to confirm their identity, relying instead on supplier certificates it had not verified.
21 CFR 211.84(d)(1)The company's stability data did not test the active ingredient or microbiological quality, so it did not show the product stays acceptable through its labeled expiry date.
21 CFR 211.166(a)The company lacked adequate written procedures and authority for its quality control unit, such as batch record review, supplier qualification, and annual product review.
21 CFR 211.22(d)
What FDA wants
FDA tells the company to correct the violations promptly and respond in writing within 15 working days, including test specifications and methods, an action plan with timelines for testing retain samples, methanol test results for all hand sanitizer batches shipped to the U.S., and a quality unit remediation plan.
Who should pay attention
- brands and retailers that buy hand sanitizer or OTC drugs from this contract manufacturer
- U.S. importers and distributors of hand sanitizer
- companies that rely on supplier certificates of analysis without verifying them
This is a summary. Read the original letter on fda.gov.